[VIRTUAL] A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics

Keytruda (pembrolizumab) - Merck (MSD)

https://meetinglibrary.asco.org/record/196008/abstract

Igor Puzanov; Patricia LoRusso; Kyriakos P. Papadopoulos; Christopher T. Chen; Yvan LeBruchec; Xiaomin He; Thierry Cousin; Karin Havenith; Joseph Boni; Johanna C. Bendell

Apr 28, 2021